PLESKOVIC, A., S.M. RAMUS, Z.J. PRAZNIKAR, M.S. LETONJA, A.C. VUJKOVAC, K. GAZDIKOVA, M. CAPRNDA, L. GASPAR, Peter KRUŽLIAK and D. PETROVIC. Polymorphism rs2073618 of the osteoprotegerin gene as a potential marker of subclinical carotid atherosclerosis in Caucasians with type 2 diabetes mellitus. VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE. BERN 9: VERLAG HANS HUBER HOGREFE AG, vol. 46, No 5, p. 355-362. ISSN 0301-1526. doi:10.1024/0301-1526/a000640. 2017.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Polymorphism rs2073618 of the osteoprotegerin gene as a potential marker of subclinical carotid atherosclerosis in Caucasians with type 2 diabetes mellitus
Authors PLESKOVIC, A. (705 Slovenia), S.M. RAMUS (705 Slovenia), Z.J. PRAZNIKAR (705 Slovenia), M.S. LETONJA (705 Slovenia), A.C. VUJKOVAC (705 Slovenia), K. GAZDIKOVA (703 Slovakia), M. CAPRNDA (703 Slovakia), L. GASPAR (703 Slovakia), Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution) and D. PETROVIC (705 Slovenia).
Edition VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, BERN 9, VERLAG HANS HUBER HOGREFE AG, 2017, 0301-1526.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.210
RIV identification code RIV/00216224:14110/17:00098765
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1024/0301-1526/a000640
UT WoS 000409311400004
Keywords in English Subclinical carotid atherosclerosis; genetic polymorphism; osteoprotegerin; type 2 diabetes mellitus
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 21/3/2018 16:21.
Abstract
Background: The OPG/RANKL/RANK (osteoprotegerin/receptor-activator of nuclear factor kappa B ligand/receptor-activator of nuclear factor kappa B) axis has been recently linked to the development of atherosclerosis and plaque destabilization. We have investigated whether polymorphism rs2073618 of the OPG gene is associated with subclinical markers of carotid atherosclerosis in subjects with type 2 diabetes mellitus (T2DM). Patients and methods: 595 subjects with T2DM were enrolled in the cross-sectional study. Subclinical markers of carotid atherosclerosis (carotid intima media thickness, plaque thickness, and plaques presence) were assessed with ultrasound at the time of recruitment. Genotyping for rs2073618 (a missense variant located in exon I of the OPG gene) was performed, and OPG serum levels were determined by ELISA. Results: Compared to the GG genotype, the CC genotype of the rs2073618 polymorphism had a significantly increased risk for the presence of carotid plaque (OR = 2.54, 95 % CI = 1.22-5.28, p = 0.01). No statistically significant difference could be detected (p = 0.68) upon comparing median values of serum OPG levels among studied genotype groups in subjects with T2DM. Multi-variable linear regression analyses in T2DM subjects demonstrated that GC and CC genotypes (p = 0.03 and p = 0.003), together with statin therapy (p = 0.009), were independent predictors of the number of carotid segments with plaques. Conclusions: Despite the fact that OPG rs2073618 genotypes failed to predict the serum OPG levels as there was no statistical difference among compared genotypes, our results demonstrate that the rs2073618 polymorphism could be a possible genetic marker for the prediction of increased risk for carotid plaque burden as a measure of advanced subclinical atherosclerosis in T2DM subjects.
PrintDisplayed: 28/3/2024 14:14